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Recently, several articles have been pub-
lished questioning the usefulness of animal 
experiments for prediction of human toxicity 
(Leist and Hartung, 2013). For example, it 
has been reported that there is almost no cor-
relation of gene expression alterations in-
duced by inflammatory stimuli in humans 
and mice (Seok et al., 2013). However, a re-
cent study of Thiel et al. (2015) demonstrates 
that this view may be too pessimistic. Based 
on pharmacokinetic modeling, Thiel et al. 
(2015) demonstrated a surprisingly precise 
mouse to human extrapolation for 10 exem-
plary pharmaceuticals. For interspecies mod-
eling the authors adjusted four parameter 
domains in PBPK models: (i) Species-
specific physiology, including more than 500 
individual parameters, for example organ 
size and blood flow; (ii) the fraction of non-
protein bound test compound; (iii) pharma-
cokinetic parameters, such as Km and Vmax 
for the predominant route of clearance, (iv) 
tissue specific gene expression of the most 
important genes responsible for elimination 
of the test compound (Thiel et al., 2015). 
Adjusting these parameter domains leads to a 
very good fit of mouse to human extrapolat-
ed plasma concentrations of the test com-
pounds compared to measured human plas-
ma concentrations. One of the limitations of 
the study of Thiel et al. (2015) is the use of 
gene expression data for simulation of the 
influence of metabolizing enzymes and car-
riers involved in clearance of the test com-
pounds. Since the activities and not RNA 
levels are relevant in this context, the RNA 
based approximation can certainly be further 
improved. However, establishment of a tis-
sue and species specific directory of all rele-
vant metabolizing activities still represents 
an important future project.  
Currently, much effort is invested in re-
search on in vitro systems (Frey et al., 2014; 
Kim et al., 2015; Hammad and Ahmed, 
2014), particularly in the fields of hepatotox-
icity (Godoy et al., 2013; Grinberg et al., 
2014; Ghallab, 2014; Schug et al., 2013), 
neurotoxicity (Balmer et al., 2014; Wald-
mann et al., 2014; Krug et al., 2013; Stöber, 
2014) and nephrotoxicity (Giustarini et al., 
2009; Faiz et al., 2011). These studies de-
pend on knowledge of in vivo relevant con-
centrations which should be covered by in 
vitro testing. A precise extrapolation of dos-
es in vivo to blood concentrations or even 
better compound concentrations at the target 
cells of toxicity is therefore critical for pro-
gress in the field of alternative methods and 
can best be achieved by systematic PBPK 
modeling (Mielke et al., 2011; Sterner et al., 
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2013; Strikwold et al., 2013; Wang et al., 
2000). Further progress may be achieved by 
combining PBPK models with the recently 
established spatio-temporal models (Hoehme 
et al., 2010; Drasdo et al., 2014a) which can 
simulate metabolism at the level of individu-
al cells (Schliess et al., 2014; Drasdo et al., 
2014b; Widera, 2014). The here discussed 
study of Thiel and colleagues improves the 
reliability of extrapolating compound con-
centrations from mice to human by the sys-
tematic adaptation of species specific model 
parameters and therefore is of high relevance 
not only for the planning of first-in-man 
studies but also for an improved use of in 
vitro systems for prediction of human toxici-
ty.  
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